Bilateral nerve-sparing RARP (n = 46) | Unilateral nerve-sparing RARP (n = 137) | |||||
---|---|---|---|---|---|---|
With HA/CMC (n = 13) | Without HA/CMC (n = 33) | P value | With HA/CMC (n = 40) | Without HA/CMC (n = 97) | P value | |
Follow-up period, months: median (IQR) | 20.7 (16.3–27.0) | 20.1 (14.9–29.4) | 0.83 | 21.6 (16.7–27.0) | 20.3 (13.3–28.5) | 0.79 |
Operating time, min: median (IQR) | 207 (178–223) | 215 (189–249) | 0.10 | 210 (176–234) | 233 (203–275) | 0.09 |
Estimated blood loss, mL: median (IQR) | 10 (2.5–125) | 20 (5–125) | 0.09 | 19 (0–88) | 70 (0–105) | 0.07 |
Complications ≥ Clavien G3, n (%) | 1 (7.7) | 3 (9.1) | 0.32 | 1 (2.5) | 2 (2.1) | 0.87 |
Urine leakage at cystography, n (%) | 1 (7.7) | 3 (9.1) | 0.81 | 4 (10.0) | 10 (10.3) | 0.96 |
pT, n (%) | 0.81 | 0.38 | ||||
pT2 | 12 (92.3) | 28 (84.8) | 29 (72.5) | 77 (79.4) | ||
≥ pT3 | 1 (7.7) | 5 (15.2) | 11 (27.5) | 20 (20.6) | ||
Gleason sum, n (%) | 0.48 | 0.50 | ||||
6 | 4 (30.8) | 7 (21.2) | 1 (2.5) | 3 (3.1) | ||
7 | 7 (53.8) | 23 (30.4) | 31 (77.5) | 85 (87.6) | ||
≥8 | 2 (15.4) | 3 (9.1) | 8 (20.0) | 9 (9.3) | ||
Positive surgical margin, n (%) | 2 (15.4) | 3 (9.1) | 0.54 | 5 (12.5) | 15 (15.5) | 0.37 |
Biochemical failure, n (%) | 0 (0) | 0 (0) | – | 2 (5.0) | 6 (6.2) | 0.79 |